HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
Effect of Raloxifene on Sexual Function in Older Postmenopausal Women With Osteoporosis
OBJECTIVE To assess the effect of raloxifene compared with placebo on sexual function in older postmenopausal women undergoing therapy for the treatment of osteoporosis . METHODS A subset ( 12 % ) of English-speaking women in the United States and Canada participating in the Multiple Outcomes of Raloxifene Evaluation Trial were asked to complete a sexual function question naire at baseline and after 36 months of treatment . The Multiple Outcomes of Raloxifene Evaluation Trial is a multicenter , r and omized , blinded , placebo-controlled clinical trial , in which 7705 postmenopausal women with osteoporosis were r and omly assigned to one of three groups : raloxifene hydrochloride 60 mg per day or 120 mg per day or placebo . In this sub study , 943 women completed the sexual function question naire at both visits . Because preliminary analyses showed no differences by raloxifene dose ( n = 302 for 60 mg per day ; n = 322 for 120 mg/day ) , the two groups were combined and compared with the placebo group ( n = 319 ) . For the given sample size , we had 80 % power ( & agr ; = .05 , two-sided , ratio of raloxifene to placebo = 2:1 ) to detect a 10%–16 % difference in the proportion of women experiencing no change in sexual function between placebo and treatment groups . RESULTS Overall , sexual function and changes in sexual function from baseline to study end between the raloxifene and placebo groups did not differ . In particular , there were no differences in sexual desire or frequency of sexual activity between the groups . Among sexually active women , there were no differences in enjoyment , satisfaction , orgasm , or reported sexual problems . CONCLUSION Sexual function in older postmenopausal women with osteoporosis is not affected by treatment with raloxifene
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .